Expression of thioredoxin-2 for monitoring minimal residual disease in acute leukemia.
10.3969/j.issn.1672-7347.2013.04.008
- Author:
Qiong LUO
1
;
Zhixin HUANG
;
Liuping LUO
;
Dingzhang XIAO
Author Information
1. Department of Hematology, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Publication Type:Journal Article
- MeSH:
Case-Control Studies;
Female;
Humans;
Leukemia, Myeloid, Acute;
diagnosis;
genetics;
metabolism;
Male;
Neoplasm, Residual;
diagnosis;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
genetics;
metabolism;
Real-Time Polymerase Chain Reaction;
Thioredoxins;
genetics;
metabolism
- From:
Journal of Central South University(Medical Sciences)
2013;38(4):383-387
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the significance of human thioredoxin-2 (TRX-2) in monitoring minimal residual disease (MRD) in acute leukemia (AL).
METHODS:We used real-time quantitative PCR to serially quantitize TRX-2 expression levels in the bone marrow of AL patients at diagnosis (n=68), at complete hematologic remission (CHR, n=57) and at relapse (n=25). Another 25 normal donors served as normal controls. The upper limit of the bone marrow at 91 was regarded as the reference. TRX-2 expression level at CHR with <5% blast cells in the bone marrow of relapse patients was analyzed and compared with MRD by flow cytometry.
RESULTS:The TRX-2 levels between the CHR patients and newly diagnosed patients, and between the CHR patients and the relapse patients had significant difference. TRX-2 expression level of 21(21/25) relapse patients at CHR with <5% blast cells in the bone marrow was higher than the reference (>91). TRX-2 level was correlated to the expression level of MRD.
CONCLUSION:TRX-2 may be the marker for AL and used in MRD monitoring.
